Jeremy Watkins, MD
Otolaryngology · Fort Worth, TXNPI 1780800938
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (30.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Acclarent, Inc at 43.1% of the total. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $161.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acclarent, Inc$7K
- Medtronic$6K
- Neurent Medical Limited$1K
- Integra Lifesciences Corporation$447
- Stryker$435
- Inspire Medical Systems, Inc.$364
- plus $1K from 17 others
Across 20 payments — averaging $13,127 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerin Medical Inc.$244K
- AstraZeneca$19K
What the payments were for
- Consulting fees$5,20030%
- Speaking & faculty fees$5,20030%
- Travel & lodging$2,69816%
- Food & beverage$4,02123%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acclarent, Inc | 18 | $7,397 |
| Medtronic(2 entities) | 19 | $5,892 |
| Neurent Medical Limited | 4 | $1,204 |
| Integra Lifesciences Corporation | 5 | $447 |
| Stryker | 9 | $435 |
| Inspire Medical Systems, Inc. | 13 | $364 |
| Intersect ENT, Inc. | 4 | $330 |
| Chitogel Limited | 2 | $282 |
| Regeneron Healthcare Solutions, Inc. | 6 | $211 |
| Aerin Medical Inc. | 3 | $128 |
| Smith+Nephew | 4 | $86 |
| Hikma Pharmaceuticals USA | 3 | $45 |
| Sanofi | 2 | $45 |
| Merck | 2 | $44 |
| GSK | 2 | $40 |
| Optinose US, Inc. | 2 | $34 |
| Olympus America Inc. | 2 | $32 |
| Pylant Medical | 1 | $30 |
| Spirair, Inc. | 1 | $28 |
| C2dx, Inc | 1 | $21 |
| Novartis | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Glenmark Therapeutics Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PTEYE PARATHYROID DETECTION SYSTEM$1,800
- ACCLARENT Balloon Inflation Device$1,356
- NEUROMARK System$1,188
- NEUROMARK Radiofrequency Console$1,188
- PROPEL$1,029
- Acclarent Aera$503
- Inspira Air$373
- RELIEVA SPINPLUS NAV$373
- TruDi Probe$373
- SINUVA$277
- Chitogel Endoscopic Sinus Surgery Kit$228
- RELIEVA SPINPLUS Balloon Sinuplasty System$204
- TruDi Nav Cable$145
- ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM$142
- SPIROX - LATERA$139
- Spine & Trauma 3D Navigation$130
- Relieva Spinplus$130
- Acclarent Navwire$110
- StealthStation$108
How this compares
$17,145 in reported general payments places this provider in the 90th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Flucytosine | 22 | $57,056 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 65 | $9,511 |
| Fluticasone Propionate | 232 | $3,749 |
| Epinephrine | 20 | $2,803 |
| Ipratropium Bromide | 64 | $2,450 |
| Montelukast Sodium | 269 | $2,198 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 96 | $1,867 |
| Azelastine Hcl | 43 | $1,551 |
| CefuroximeCefuroxime Axetil | 57 | $1,284 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 12 | $1,209 |
| Fluocinolone Acetonide Oil | 24 | $1,023 |
| Omeprazole | 55 | $991 |
| Mupirocin | 45 | $925 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 88 | $837 |
| Doxycycline Monohydrate | 33 | $788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $45 | $2,80320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Fort Worth
- Marc DeanFort Worth$486K
- Jesse SmithFort Worth$16K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
- Martin CitardiHouston$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.